Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

Beumer, J H; Rademaker-Lakhai, J M; Rosing, H; Lopez-Lazaro, L; Beijnen, J H; Schellens, J H M

Beumer, J H; Rademaker-Lakhai, J M; Rosing, H; Lopez-Lazaro, L; Beijnen, J H; Schellens, J H M.

Affiliation

Beumer JH; Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. beumerjh@upmc.edu

Invest New Drugs ; 23(5): 429-36, 2005 Oct.

Article in En | MEDLINE | ID: mdl-16133794

Subject(s)

Antineoplastic Agents, Alkylating/pharmacokinetics; Dioxoles/pharmacokinetics; Isoquinolines/pharmacokinetics; Adult; Aged; Antineoplastic Agents, Alkylating/blood; Antineoplastic Agents, Alkylating/urine; Area Under Curve; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Dioxoles/blood; Dioxoles/urine; Feces/chemistry; Female; Half-Life; Humans; Isoquinolines/blood; Isoquinolines/urine; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Sarcoma; Sarcoma, Synovial; Tetrahydroisoquinolines; Trabectedin

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Agents, Alkylating / Dioxoles / Isoquinolines Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2005 Document type: Article Affiliation country: Netherlands Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links